Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX and Bevacizumab in Advanced Neuroendocrine Tumors
NCT00227617Phase 3Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jun 2005
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in Neuroendocrine Neoplasm (NEN), sponsored by University of California, San Francisco. Started Jun 2005; status: terminated.
02
Drugs
bevacizumab
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00227617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227617.